Chloroquine resistance before and after its withdrawal in Kenya

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa

The selection of point mutation at codon 164 (from isoleucine to leucine) of the dihydrofolate reductase (DHFR) enzyme in Plasmodium falciparum is associated with high sulfadoxine /pyrimethamine (SP) resistance. Using the yeast expression system that allows the detection of dhfr allele present at low level, the presence of this mutation had previously been reported between 1998–1999 in Muheza, Tanzania, an area of high SP resistance. Eighty five P. falciparum isolates, obtained from the same area between 2002 and 2003, were analysed for the presence of Leu-164 mutation, using standard protocol based on PCR-RFLP. None of the isolates had the Leu-164 mutation

Preparation of Silver/Chitosan Nanofluids Using Selected Plant Extracts: Characterization and Antimicrobial Studies against Gram-Positive and Gram-Negative Bacteria

Chitosan/silver nanofluids were prepared using Phoenix dactylifera (DPLE) or Rumex vesicarius (HEL) extracts as the reducing agent, characterized using Fourier-transform infrared spectroscopy (FTIR), ultraviolet–visible (UV-vis), X-ray di�raction (XRD), and transmission electron microscope (TEM). The antimicrobial e�ect of the nanofluids against Gram positive, Bacillus licheniformis, Staphylococcus haemolyticus, Bacillus cereus, and Micrococcus luteus, and Gram-negative Pseudomonas aeruginosa, Pseudomonas citronellolis, and Escherichia coli bacteria has been studied. The nanoparticles were polydispersed in the chitosan matrix and are highly stable. The zeta potential of the silver nanoparticles in DPLE- and HEL-mediated composites is +46 mV and +56 mV, respectively. The FTIR results reveal that the free carboxylate groups in the plant biomaterial took part in stabilization process. HEL is a stronger reducing agent than DPLE and nanoparticles generated with HEL are smaller (8.0–36 nm) than those produced with DPLE (10–43 nm). DPLE- and HEL-mediated composites e�ectively inhibit the growth of the studied bacteria but HEL-mediated composite exhibited higher e�ect. The higher antimicrobial activity of HEL-mediated composite is linked to the smaller nanoparticles. The foregoing results indicate that HEL extract can be used in the green production of potential antimicrobial chitosan/silver nanofluids for biomedical and packaging applications

Enhanced biodegradation of phenanthrene and anthracene using a microalgal-bacterial consortium

Polycyclic aromatic hydrocarbons (PAHs) are chemicals that are released into the environment during activities of the petroleum industry. The bioaccumulation, carcinogenic and mutagenic potential of PAHs necessitates the bioremediation of these contaminants. However, bioremediation of PAHs has a number of limitations including the inability of a single microbe to degrade all of the PAH fraction’s environmental constituents. Therefore, a different paradigm, employing microalgal-bacterial consortium (MBC), may be used to effectively remove PAHs contaminants. In this type of interaction, the microalgae and bacteria species in the consortium work together in a way that enhances the overall performance of the MBC. Bacterial species in the consortium provide essential nutrients or growth factors by degrading toxic substances and provide these to microalgae, while the microalgae species provide organic carbon for the bacterial species to grow. For the first time, the ability of Gonium pectorale (G. pectorale) microalgae to break down phenanthrene (PHE) and anthracene (ANT) was investigated. Phenanthrene was shown to be more effectively degraded by G. pectorale (98%) as compared to Bacillus licheniformis (B. licheniformis) 19%. Similarly, G. pectorale has effectively degrade anthracene (98%) as compared with B. licheniformis (45%). The consortia of G. pectorale and B. licheniformis has shown a slight increase in the degradation of PHE (96%) and ANT (99%). Our findings show that B. licheniformis did not inhibit the growth of G. pectorale and in the consortia has effectively eliminated the PAHs from the media. Therefore G. pectorale has a tremendous potential to remove PAHs from the polluted environment. Future research will be conducted to assess Gonium’s capacity to eliminate PAHs that exhibit high molar masses than that of PHE and ANT

Corrosion Inhibition of Rumex vesicarius Mediated Chitosan-AgNPs Composite for C1018 CS in CO2-Saturated 3.5% NaCl Medium under Static and Hydrodynamic Conditions

Rumex vesicarius (RVE) mediated chitosan–AgNPs composite was produced in situ by using an aqueous extract of Rumex vesicarius leaves as the reducing agent to reduce Ag+ to Ag0. The synthesized composite was evaluated as a sweet (CO2) corrosion inhibitor (CI) for C1018 carbon steel (CS) in 3.5 wt% NaCl solution under static and hydrodynamic conditions. The corrosion inhibitive performance was evaluated using electrochemical impedance spectroscopy (EIS), linear polarization resistance (LPR), and potentiodynamic polarization (PDP) techniques, as well as scanning electron microscopy (SEM)/energy dispersive X-ray spectroscopy (EDAX), and atomic force microscopy (AFM) on corroded C1018 CS without and with additives. The effect of concentration, immersion time, temperature, and rotation speed on the CI performance of the composite was also investigated. The corrosion inhibitive effect increased with increasing composite dosage, with the highest inhibition efficiency (IE) acquired at the maximum composite dosage of 0.3%. Beyond this concentration, the IE decline with increasing concentration. Furthermore, IE was found to increase with immersion time and decline with a temperature rise from 25 to 40 �C, with the optimum temperature of 60 �C found to accelerate corrosion without and with RVE-mediated Chi–AgNPs composite. Under high shear stress, the Chi–AgNPs composite exhibits moderate corrosion inhibition under hydrodynamic conditions. The surface analysis results validate the formation of a protective covering due to composite adsorption on the CS surface. The RVE-mediated chitosan–AgNPs composite could be recommended as a CI for C1018 CS in sweet (CO2) corrosion environments at ambient temperatur

Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax

Resistance of vivax malaria to treatment with antifolates, such as pyrimethamine (Pyr), is spreading as mutations in the dihydrofolatereductase (dhfr) genes are selected and disseminated. We tested the antitumor drug methotrexate (MTX), a potent competitive inhibitor of dhfr, against 11 Plasmodium vivax isolates ex vivo, 10 of which had multiple dhfr mutations associated with Pyr resistance. Despite high-grade resistance to Pyr (median 50% inhibitory concentration [IC50], 13,345 nM), these parasites were all highly susceptible to MTX (median IC50, 2.6 nM). Given its potency against Pyr-resistant P. vivax, the antimalarial potential of MTX deserves further investigation

A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers

<p>Abstract</p> <p>Background</p> <p>Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. A phase I evaluation was conducted to assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers.</p> <p>Methods</p> <p>Twenty five healthy adult volunteers were recruited and admitted to receive a 5 mg dose of methotrexate/day/5 days. Pharmacokinetics blood sampling was carried out at 2, 4, 6, 12 and 24 hours following each dose. Nausea, vomiting, oral ulcers and other adverse events were solicited during follow up of 42 days.</p> <p>Results</p> <p>The mean age of participants was 23.9 ± 3.3 years. Adherence to protocol was 100%. No grade 3 solicited adverse events were observed. However, one case of transiently elevated liver enzymes, and one serious adverse event (not related to the product) were reported. The maximum concentration (C_max) was 160-200 nM and after 6 hours, the effective concentration (C_eff) was <150 nM.</p> <p>Conclusion</p> <p>Low-dose methotraxate had an acceptable safety profile. However, methotrexate blood levels did not reach the desirable C_effof 250-400-nM required to clear malaria infection <it>in vivo</it>. Further dose finding and safety studies are necessary to confirm suitability of this drug as an anti-malarial agent.</p